Exploring the Possibility of Unique Molecular, Biological, and Tissue Effects With Hypofractionated Radiotherapy

Seminars in Radiation Oncology

Volumn 18, Issue 4, 2008, Pages 244-248

  Story, Michael ^a   Kodym, Reinhard ^a   Saha, Debabrata ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPROTECTIVE AGENT; RADIOSENSITIZING AGENT;

ARTICLE; CANCER RADIOTHERAPY; GENETICS; HYPOFRACTIONATED RADIOTHERAPY; HYPOXIA; MOLECULAR BIOLOGY; POPULATION DYNAMICS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION PROTECTION; RADIOBIOLOGY; RADIOSENSITIVITY; RADIOSENSITIZATION; REOXYGENATION; TISSUE REACTION;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; RADIATION INJURIES; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS; RADIOBIOLOGY; STEREOTAXIC TECHNIQUES;

EID: 49749112884     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.04.006     Document Type: Article

References (36)

1. Blomgren H., Lax I., Naslund I., et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34 (1995) 861-870
2. Hiraoka M., Matsuo Y., and Nagata Y. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer. Cancer Radiother 11 (2007) 32-35
3. Timmerman R., Papiez L., McGarry R., et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124 (2003) 1946-1955
4. Jin L., Wang L., Li J., et al. Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using Monte Carlo dose calculations. Phys Med Biol 52 (2007) 3549-3561
5. Cardinale R.M., Wu Q., Benedict S.H., et al. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 45 (1999) 515-520
6. Giraud P., Kantor G., Loiseau H., et al. Target definition in the thorax and central nervous system. Semin Radiat Oncol 15 (2005) 146-156
7. Forgacs E., Zochbauer-Muller S., Olah E., et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7 (2001) 6-13
8. Siegfried J.M., Weissfeld L.A., Singh-Kaw P., et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57 (1997) 433-439
9. Hu B., Wu L., Han W., et al. The time and spatial effects of bystander response in mammalian cells induced by low dose radiation. Carcinogenesis 27 (2006) 245-251
10. Shuryak I., Sachs R.K., and Brenner D.J. Biophysical models of radiation bystander effects: 1. Spatial effects in three-dimensional tissues. Radiat Res 168 (2007) 741-749
11. Ma L., Xia P., Verhey L.J., et al. A dosimetric comparison of fan-beam intensity modulated radiotherapy with gamma knife stereotactic radiosurgery for treating intermediate intracranial lesions. Int J Radiat Oncol Biol Phys 45 (1999) 1325-1330
12. Yi S., Chen J.R., Viallet J., et al. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br J Cancer 77 (1998) 2162-2170
13. Mothersill C., and Seymour C.B. Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium. Radiat Res 149 (1998) 256-262
14. Rossi L., Reverberi D., Podesta G., et al. Co-culture with human fibroblasts increases the radiosensitivity of MCF-7 mammary carcinoma cells in collagen gels. Int J Cancer 85 (2000) 667-673
15. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N Engl J Med 355 (2006) 1253-1261
16. Blazek E.R., Foutch J.L., and Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67 (2007) 1-5
17. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
18. Phillips T.M., McBride W.H., and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98 (2006) 1777-1785
19. Conger A.D. The effect of oxygen on the radiosensitivity of mammalian cells. Radiology 66 (1956) 63-69
20. Du Sault L. Reoxygenation of tumors during fractionated radiotherapy. Radiobiology 92 (1969) 626-628
21. Li C., Wright M.M., and Jackson R.M. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp Lung Res 28 (2002) 373-389
22. Petersen C., Zips D., Krause M., et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 51 (2001) 483-493
23. Nakamura K., and Brahme A. Evaluation of fractionation regimens in stereotactic radiotherapy using a mathematical model of repopulation and reoxygenation. Radiat Med 17 (1999) 219-225
24. Fujino M., Shirato H., Onishi H., et al. Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J 12 (2006) 41-46
25. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24 (2006) 4833-4839
26. Timmerman R., Bastasch M., Saha D., et al. Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40 (2007) 352-365
27. Dikomey E., Brammer I., Johansen J., et al. Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. Int J Radiat Oncol Biol Phys 46 (2000) 481-490
28. Geara F.B., Peters L.J., Ang K.K., et al. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation. Cancer Res 52 (1992) 6348-6352
29. Bentzen S.M. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol 43 (1997) 121-131
30. Tucker S.L., Geara F.B., Peters L.J., et al. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity?. Radiother Oncol 38 (1996) 103-113
31. Rades D., Fehlauer F., Bajrovic A., et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70 (2004) 261-264
32. Koukourakis M.I. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol 29 suppl 19 (2002) 42-46
33. Le Q.T., Loo B.W., Ho A., et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 1 (2006) 802-809
34. Brenner D.J., Martel M.K., and Hall E.J. Fractionated regimens for stereotactic radiotherapy of recurrent tumors in the brain. Int J Radiat Oncol Biol Phys 21 (1991) 819-824
35. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
36. Park C., Papiez L., Zhang S., et al. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 847-852